ArticleAMB Express2026
Agaricus arvensis extract-coated functionalized silver nanoparticles for effective aerobic biotransformation of synthetic L-tyrosine to L-DOPA.
Article in AMB Express, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study presents a green nanobiotechnological platform for enhanced L-DOPA biosynthesis. Intracellular tyrosine hydroxylase (TH) was immobilized onto silver nanoparticles (AgNPs) biosynthesized using extract of the edible mushroom Agaricus arvensis and subsequently applied for the aerobic biotransformation of synthetic L-tyrosine. The AgNPs were produced using the mushroom extract as a natural reducing agent and optimized for "TH" activity under controlled conditions: 2.5% (w/v) biomass concentration, peptone-saline medium, 90 °C, and 24 min reaction time. Various analytical techniques such as UV-Vis spectroscopy, SEM, FTIR and XRD were used to confirm the synthesis and characterization of the AgNPs. The particle size was further validated by Scanning Electron Microscopy (SEM), revealing an average size of 88.49 ± 3.83 nm. The particle size was further analyzed by a Zeta-sizer, which showed a Z-average size of 163.7 d.nm. When applied in the biotransformation of synthetic L-tyrosine, the AgNP-immobilized enzyme significantly outperformed the free enzyme, yielding a 2.54-fold increase in L-DOPA production within 1.5 h. These results indicate that Agaricus arvensis-derived AgNPs not only stabilize the enzyme but also boost its activity, providing a sustainable and efficient approach for producing L-DOPA. This method holds promise for large-scale applications in pharmaceutical manufacturing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.